骨關節炎藥物市場規模、佔有率和成長分析（按藥物類型、解剖結構、給藥途徑、銷售管道、最終用途和地區）- 行業預測 2025-2032

2023 年骨關節炎治療市場規模價值為 95 億美元，預計將從 2024 年的 101.6 億美元成長到 2032 年的 173.2 億美元，預測期內（2025-2032 年）的複合年成長率為 6.9%。

根據 2023 年 1 月 CDC 的資料，骨關節炎影響超過 3,250 萬美國，預計市場將顯著成長。盛行率的急劇上升，尤其是在老年人和女性中，凸顯了對有效治療的迫切需求。肌肉骨骼異常和荷爾蒙變化等因素會增加女性患病的風險，而女性中更為普遍的肥胖則進一步導致患病風險。隨著該領域研究和開發的不斷深入，創新的治療方案不斷湧現，尤其是透過關節內給藥和緩解疾病的藥物。由於這些進展和對骨關節炎的了解不斷加深，市場預計會擴大，因此有明顯的機會採取有針對性的干涉措施來應對這一重大的健康挑戰。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

骨關節炎藥物市場規模（按藥物類型和複合年成長率） (2025-2032)

• 市場概況
• 關節內粘稠補充療法治療
• 非類固醇消炎劑
  • 萘普生
  • 阿斯匹靈
  • 雙氯芬酸鈉
  • Ibuprofen
  • 塞來昔布
  • 美洛康
  • Piroxicam
  • 酮洛芬
  • 其他 NSAID
• 止痛藥
  • Duloxetine
  • 乙醯胺酚
• 皮質類固醇
• 其他

骨關節炎藥物市場規模（按解剖學和複合年成長率） (2025-2032)

• 市場概況
• 膝關節骨關節炎
• 髖關節骨關節炎
• 手部骨關節炎
• 其他

骨關節炎治療藥物市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概況
• 腸外給藥
  • 玻尿酸注射
  • 皮質類固醇注射
  • 富血小板血漿 (PRP) 注射
  • 胎盤組織基質（PTM）注射
  • 乙醯水楊酸（ASA）注射劑
  • 其他
• 局部路線
• 口服

骨關節炎治療藥物市場規模（銷售管道及複合年成長率）（2025-2032）

• 市場概況
• 處方藥
• 非處方藥

骨關節炎藥物市場規模（依最終用途和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 其他

骨關節炎治療藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Sanofi SA（France）
• Johnson & Johnson（USA）
• Eli Lilly and Company（USA）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• Regeneron Pharmaceuticals, Inc.（USA）
• Flexion Therapeutics, Inc.（USA）
• Seikagaku Corporation（Japan）
• TissueGene, Inc.（South Korea）
• Anika Therapeutics, Inc.（USA）
• Ampio Pharmaceuticals, Inc.（USA）
• BioDelivery Sciences International, Inc.（USA）
• Bone Therapeutics SA（Belgium）
• Kolon TissueGene, Inc.（South Korea）
• Centrexion Therapeutics Corporation（USA）
• Kiniksa Pharmaceuticals, Ltd.（Bermuda）

結論和建議

Osteoarthritis Therapeutics Market size was valued at USD 9.5 billion in 2023 and is poised to grow from USD 10.16 billion in 2024 to USD 17.32 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The osteoarthritis market is poised for significant growth, with over 32.5 million Americans affected, according to January 2023 CDC data. This surge in prevalence, particularly among older adults and women, underscores the critical demand for effective therapies. Factors such as musculoskeletal abnormalities and hormonal changes contribute to the heightened risk in women, while obesity, which is more common among females, further predisposes them to the condition. As research and development in this area intensify, innovative treatment solutions, particularly through intra-articular drug administration and disease-modifying medications, are emerging. With the market expected to expand due to these advancements and a deeper understanding of osteoarthritis, there's a clear opportunity for targeted interventions that address this significant health challenge.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoarthritis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoarthritis Therapeutics Market Segments Analysis

Global Osteoarthritis Therapeutics Market is segmented by Drug Type, Anatomy, Route of Administration, Sales Channel, End Use and region. Based on Drug Type, the market is segmented into Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids and Others. Based on Anatomy, the market is segmented into Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis and Others. Based on Route of Administration, the market is segmented into Parenteral Route, Topical Route and Oral Route. Based on Sales Channel, the market is segmented into Prescription Drugs and Over-the-Counter Drugs. Based on End Use, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Osteoarthritis Therapeutics Market

The global osteoarthritis therapeutics market is poised for significant growth, particularly within the rapidly aging populations in developed regions like North America and Europe. As the number of elderly individuals rises, the prevalence of joint degenerative diseases also increases, leading to a greater need for effective treatment options. This surge in demand not only propels market growth but also fosters innovation within the therapeutic landscape, as pharmaceutical companies and researchers strive to develop novel and improved solutions for osteoarthritis management. Consequently, the combination of demographic trends and the corresponding healthcare needs creates a robust environment for market expansion.

Restraints in the Osteoarthritis Therapeutics Market

A significant restraint in the Osteoarthritis Therapeutics market stems from the potential side effects linked to traditional treatments like NSAIDs and corticosteroids. The extended use of these medications can result in serious complications, including gastrointestinal disorders and cardiovascular diseases. This adverse effect profile makes patients hesitant to rely on these conventional therapies, prompting them to explore alternative options instead. Consequently, the undesirable nature of these drugs hampers their widespread acceptance and limits their usage in the mainstream treatment of osteoarthritis, ultimately impacting market growth and development. As patients prioritize safety, the demand for safer, more effective alternatives continues to rise.

Market Trends of the Osteoarthritis Therapeutics Market

The Osteoarthritis Therapeutics market is witnessing a notable trend towards the rising adoption of minimally invasive treatments, such as viscosupplementation and biologic injections. These innovative therapies offer effective pain relief and enhance joint function while significantly minimizing recovery times compared to traditional surgical interventions. As patients increasingly seek alternatives that allow for quicker return to daily activities, and as healthcare providers recognize the benefits of these less invasive options, the demand for minimally invasive solutions in osteoarthritis management is expected to grow. This shift not only improves patient satisfaction but also reflects an evolving landscape in arthritis care that prioritizes efficiency and quality of life.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Osteoarthritis Therapeutics Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Viscosupplementation Agents
• Nonsteroidal Anti-inflammatory Drugs
  • Naproxen
  • Aspirin
  • Diclofenac
  • Ibuprofen
  • Celecoxib
  • Meloxicam
  • Piroxicam
  • Ketoprofen
  • Other NSAIDs
• Analgesics
  • Duloxetine
  • Acetaminophen
• Corticosteroids
• Others

Global Osteoarthritis Therapeutics Market Size by Anatomy & CAGR (2025-2032)

• Market Overview
• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis
• Others

Global Osteoarthritis Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Parenteral Route
  • Hyaluronic Acid Injections
  • Corticosteroid Injections
  • Platelet-rich Plasma (PRP) Injections
  • Placental Tissue Matrix (PTM) Injections
  • Acetylsalicylic Acid (ASA) Injections
  • Others
• Topical Route
• Oral Route

Global Osteoarthritis Therapeutics Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-the-Counter Drugs

Global Osteoarthritis Therapeutics Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Osteoarthritis Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • US
  • Canada
• Europe (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Anatomy, Route of Administration, Sales Channel, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flexion Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seikagaku Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TissueGene, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ampio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioDelivery Sciences International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bone Therapeutics SA (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kolon TissueGene, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centrexion Therapeutics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiniksa Pharmaceuticals, Ltd. (Bermuda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations